Albert Labs International Corp

Albert Labs International Corp. operates as a research and drug development company. The firm is focused on active compounds in the treatment of mental health and providing rapid access to effective prescription medicines for people suffering from mental health disorders. The firm operates primarily in one business segment: research and development of drugs to ensure accelerated access to safe and effective psychedelic-assisted therapy for patients with urgent, unmet needs. The firm also focuses on developing solutions through an approved, fast-track clinical pathway focusing on Real World Evidence (RWE). Its first drug target, KRN-101, is a potential solution for cancer-related anxiety. KRN-101 is derived from natural psilocybin mycelium. Through collaborations with research institutions, hospital centers and government agencies, the Company uses existing clinical infrastructure to deliver and improve patient access to its treatment.